Clinical trial
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously…
NCT00079040 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00079040 |
|---|---|
| Title | Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer |
| Official title | A Phase II Study of Cisplatin Plus Etoposide (PE) Plus Bevacizumab (NSC #704865) for Previously Untreated Extensive Stage Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | cisplatin, etoposide, bevacizumab, laboratory biomarker analysis |
| Enrollment | 65 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Mar 9, 2004 |
| Last update posted | May 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: